Iron in the brain: An important contributor in normal and diseased states

Neuroscientist

Volumn 6, Issue 6, 2000, Pages 435-453

  Pinero, D J ^a   Connor, J R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Brain; Iron; Myelin; Neurodegenerative diseases; Oxidative injury

Indexed keywords

IRON; MYELIN; REACTIVE OXYGEN METABOLITE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; ATTENTION; BEHAVIOR; BRAIN CELL; CENTRAL NERVOUS SYSTEM; COGNITION; FRIEDREICH ATAXIA; HALLERVORDEN SPATZ DISEASE; HUMAN; IRON DEFICIENCY; IRON METABOLISM; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROTRANSMISSION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW;

EID: 0033750537     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385840000600607     Document Type: Review

References (222)

1. Iron metabolism: A comprehensive review
2. Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport
3. Cloning and characterization of a mammalian proton-coupled metal-ion transporter
4. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse
5. A novel mammalian iron-regulated protein involved in intracellular iron metabolism
6. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding
7. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
8. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression
9. Identification of the intermolecular disulfide bonds of the human transferrin receptor and its lipid attachment site
10. pH and the recycling of transferrin during receptor-mediated endocytosis
11. Mechanism of ferritin iron uptake: Activity of the H-chain and deletion mapping of the ferro-oxidase site
12. Expression and structure and functional properties of human ferritin L-chain from Escherichia coli
13. Evidence that H- and L-chains have cooperative roles in the iron-uptake mechanism of human ferritin
14. An x-ray scattering study of ferritin and apoferritin
15. Iron metabolism - New perspectives in view
16. Characteristics and expression of binding sites specific for ferritin H-chain on human cell lines
17. Characteristics of the membrane receptor for human H-ferritin
18. Characterization of the ferritin receptors of human T lymphoid (MOLT-4) cells
19. Characterization and distribution of ferritin binding sites in the adult mouse brain
20. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains
21. Iron regulates ferritin mRNA translation through a segment of its 5' untranslated region
22. A stem-loop in the 3' untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm
23. Binding of cytosolic aconitase to the iron responsive element of porcine mitochondrial aconitase mRNA
24. Translational control of 5-aminolevulinate synthase mRNA by iron-responsive elements in erythroid cells
25. Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs
26. A specific mRNA-binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA
27. Cellular regulation of the iron-responsive element binding protein: Disassembly of the cubane iron-sulfur cluster results in high affinity RNA binding
28. Iron and gene expression: Molecular mechanisms regulating cellular iron homeostasis
29. Regulation of iron metabolism in eukaryotes
30. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress
31. Recently identified molecular aspects of intestinal iron absorption
32. Discovery of the ceruloplasmin homologue hephaestin: New insight into the copper/iron connection
33. Biochemistry of iron uptake
34. Brain iron: Location and function
35. Iron in the brain
36. Iron deficiency and educational deficiency
37. Iron and learning potential in childhood
38. Psychomotor development and behavior in iron-deficient anemic infants
39. Abnormal brain monoamine metabolism in iron deficiency anemia
40. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains
41. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease
42. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzeimer's diseased brains
43. Receptor-mediated endocytosis of transferrin at the blood-brain-barrier
44. Iron and neurotransmitter function in the brain
45. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo
46. Iron and transferrin uptake by brain and cerebrospinal fluid in the rat
47. Importance of fetal and neonatal iron: Adequacy for normal development of central nervous system
48. Uptake and distribution of iron and transferrin in the adult rat brain
49. Transferrin receptor on endothelium of brain capillaries
50. Iron regulation in the brain at the cell and molecular level
51. Iron uptake in blood-brain barrier endothelial cells cultured in iron-depleted and iron-enriched media
52. Studies of the mechanism of iron transport across the blood-brain barrier
53. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells
54. Receptor-mediated transcytosis of transferrin across the blood-brain barrier
55. Immunohistochemical analysis of transferrin receptor: Regional and cellular distribution in the hypotransferrinemic (hpx) mouse brain
56. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier
57. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: A comparative immunohistochemical analysis
58. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease
59. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases
60. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system
61. Kinetics and distribution of [59Fe-125I] transferrin injected into the ventricular system of the rat
62. Effects of diet and development upon the uptake and distribution of cerebral iron
63. Transferrin is required for normal distribution of 59Fe and 54Mn in mouse brain
64. Citrate and alpha-ketoglutarate in cerebrospinal fluid and blood
65. Vitamin homeostasis in the central nervous system
66. Transport of iron in the blood-brain-cerebrospinal fluid system
67. Abnormalities in CSF concentrations of ferritin and transferrin in restless leg syndrome
68. Cerebrospinal fluid ferritin levels in screening for meningism
69. The clinical relevance of ferritin concentration in the cerebrospinal fluid
70. Cerebrospinal fluid ferritin in human disease
71. Cerebrospinal fluid ferritin in brain necrosis: Evidence for local synthesis
72. Iron deposits surrounding multiple sclerosis plaques
73. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain
74. Cellular distribution of iron in the brain of the Belgrade rat
75. Transition elements and the nervous system
76. MR evaluation of age-related increase of brain iron in young adult and older normal males
77. The effect of age on the non-haemin iron in the human brain
78. Normal deposition of brain iron in childhood and adolescence: MRI imaging at 1.5T
79. A histochemical study of iron-positive cells in the developing rat brain
80. Iron, transferrin, and ferritin in the rat brain during development and aging
81. Developmental changes in transferrin and iron uptake by the brain in the rat
82. Regional brain, iron, ferritin, and transferrin concentrations during iron deficiency and iron repletion in developing rats
83. Brain iron, transferrin and ferritin concentrations are altered in developing iron-deficient rats
84. Expression of the transferrin gene during development of non-hepatic tissues: High levels of transferrin mRNA in fetal muscle and adult brain
85. Expression of transferrin mRNA in the CNS of normal and jimpy mice
86. Relationship of iron to oligodendrocytes and myelination
87. Cellular distribution of ferritin subunits in postnatal rat brain
88. Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry
89. Differential expression of the heavy chain ferritin gene in non-adhered and adhered oligodendrocytes
90. The expression of ferritin subunits and iron in oligodendrocytes in neonatal porcine brains
91. Distribution of brain iron, ferritin, and transferrin in the 28-day-old piglet
92. Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease
93. Transferrin receptors in rat brain: Neuropeptide-like pattern and relationship to iron distribution
94. Transferrin receptor in rat central nervous system. An immunohistochemical study
95. Cellular management of iron in the brain
96. Characterization and distribution of transferrin receptors in the rat brain
97. A model of brain iron transport: The Belgrade rat
98. Long-term consequences of early iron deficiency on dopaminergic neurotransmission
99. Selective alteration in blood brain barrier and insulin transport in iron-deficient rats
100. Variations in dietary iron alter brain iron metabolism in developing rats
101. Brain iron: Persistent deficiency following short term iron deprivation the young rat
102. Brain iron in the rat: Extremely slow turnover in normal rats may explain the long lasting effects of early iron deficiency
103. Iron deficiency during development in the rat: Behavioral and physiological consequences
104. Long term effects of early iron deficiency on consummatory behavior in the rat
105. The effects of therapy on the developmental scores of iron-deficient infants
106. Effects of iron therapy on behavior performance in nonanemic, iron-deficient infants
107. Iron deficiency and cognitive function
108. Behavioral aspects of iron deficiency
109. Impact of iron deficiency on cognition in infancy and childhood
110. Exploratory mechanisms for poorer development in iron-deficient anemic infants
111. Effect of prenatal iron deficiency on myelination in rat pups
112. Feed efficiency and norepinephrine turnover in iron deficiency
113. Nutritional iron and dopamine binding sites in the rat brain
114. Brain iron and dopamine receptor function
115. Altered monoamine metabolism in caudate-putamen of iron-deficient rats
116. In vivo dopamine is altered in iron-deficient anemic rats
117. Functional studies of the central catecholamines
118. Different forms of post-training memory processing
119. The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats
120. Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in rats
121. Severe or marginal iron deficiency affects spontaneous physical activity in rats
122. Brain iron and behavior of rats are not normalized by treatment of iron deficiency anemia during early development
123. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: Delayed maturation of auditory brainstem responses
124. Reversal of developmental delays in iron-deficient anaemic infants treated with iron
125. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy
126. Hallervorden-Spatz syndrome and brain iron metabolism
127. The nosology of Hallervorden-spatz disease
128. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13
129. Hallervorden-Spatz disease: Cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus
130. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain
131. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging
132. Regional brain trace-element studies in Alzheimer's disease
133. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions
134. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study
135. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains
136. Abnormal localization of iron regulatory protein in Alzheimer's disease
137. Aluminum, iron and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide
138. Iron levels modulate α-secretase cleavage of amyloid precursor protein
139. Alzheimer's mutation
140. The free radical antioxidant vitamin E protects conical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: Relevance to the free radical hypothesis of Alzheimer's disease
141. Studies in Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue
142. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
143. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
144. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegnerative diseases affecting the basal ganglia
145. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
146. The role of iron in the basal ganglia
147. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
148. Increased basal ganglia iron levels in Huntington disease
149. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
150. Iron-melanin complex in substantia nigra of parkinsonian brains: An x-ray microanalysis
151. Decreased ferritin levels in brain in Parkinson's disease
152. Distribution of metal ions in the subcellular fractions of several rat brain areas
153. Proteins of iron regulation in the brain in Alzheimer's disease
154. Effects of low-iron status and deficiency of essential fatty acids on some biochemical constituents of rat brain
155. Nonidentical distribution of transferrin and iron in rat brain
156. Histochemical distribution of non-haem iron in the human brain
157. Iron uptake in the brain of the myelin deficient rat
158. Altered cellular distribution of iron in the CNS of myelin deficient rats
159. Transferrin in the central nervous system of the shiverer mouse myelin mutant
160. Oligodendrocytes and myelin sheaths in normal, quaking and shiverer brains are enriched in iron
161. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: Increased iron content?
162. Comparative immunocytochemistry of Pelizaeus-Merzbacher disease, the jimpy mouse, and the myelin-deficient rat
163. Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome
164. Changes in glial cell markers in recent and old demyelinated lesions in central pontine myelinolysis
165. White matter disorders
166. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent
167. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients
168. Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis
169. Nitric oxide mediates iron release from ferritin
170. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes
171. Tellurium blocks cholesterol synthesis by inhibiting squalene metabolism: Preferential vulnerability to this metabolic block leads to peripheral nervous system demyelination
172. Oxidation of tricarboxylic acid cycle intermediates by nerve cell bodies and glial cells
173. Oligodendrocyte associated enzymes
174. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor-mediated endocytosis
175. Clinical features and classification of inherited ataxias
176. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion
177. Frataxin gene of Freidreich's ataxia is targeted to mitochondria
178. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
179. Molecular genetics and pathogenesis of Friedreich's ataxia
180. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin
181. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue
182. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia
183. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
184. Recent insights into the molecular pathogenesis of Huntington disease
185. Mitochondrial dysfunction in neurodegenerative diseases
186. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia
187. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects
188. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group
189. Therapy in restless legs syndrome
190. Restless legs syndrome
191. Iron status and restless legs syndrome in the elderly
192. Iron and the restless legs syndrome
193. Magnetic resonance image measurement of regional brain iron content in patients with restless legs syndrome
194. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration
195. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies
196. Insight into the pathophysiology of restless legs syndrome
197. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism
198. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans
199. CSF abnormalities in patients with aceruloplasminemia
200. Aceruloplasminemia
201. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes
202. Use of desferrioxamine in the treatment of aceruloplasminemia
203. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis
204. The iron content of the tissues in hemochromatosis, with special reference to the brain
205. Deposition of iron in the periventricular areas of the human brain in hemochromatosis
206. The neuropathological changes in hemochromatosis
207. Hereditary haemochromatosis: A case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome
208. The basal ganglia in haemochromatosis
209. Body iron stores and early neurologic deterioration in acute cerebral infarction
210. MRI in tardive dyskinesia: Shortened left caudate T2
211. Tardive dyskinesia and oxidative stress
212. Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid
213. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: Implications in neuropsychiatric manifestations in porphyrias
214. Iron mobilization by succinylacetone methyl ester in rats. A model study for hereditary tyrosinemia and porphyrias characterized by 5-aminolevulinic acid overload
215. Iron deficiency of liver, heart, and brain in newborn infants of diabetic mothers
216. Nutrients, neurotransmitters and infant behavior
217. Developmental outcome of offspring of pregestational diabetic mothers
218. Neurobehaviour of school age children born to diabetic mothers
219. Neurodevelopmental outcome at early school age of children born to mothers with gestational diabetes
220. The role of iron in neurodegenerative disease